Settling a lawsuit over allegedly misleading statements is hardly the ideal backdrop for unveiling plans to list a subsidiary, but that is where ASP Isotopes recently found itself. The advanced-materials company, listed on the Nasdaq with a secondary listing on the JSE, has agreed to pay $9.35m to settle a shareholder class action suit alleging that it overstated its uranium-enrichment capabilities in 2024. The settlement remains subject to court approval and resolves the case without any judicial finding that the allegations were proved.
The business earmarked for the spin-out is Renergen, the former JSE-listed South African helium hopeful that ASP acquired in January through a share scheme granting investors 0.09196 ASP shares for every Renergen share held.
ASP’s JSE performance has since disappointed. At roughly R65 a share, the exchange ratio translates into an implied value of about R6 a share for each former Renergen share, leaving investors who held through the transaction still underwater.
ASP’s wider portfolio spans specialist isotopes used in electronics, nuclear medicine and nuclear fuels. Its three enrichment plants are in Pretoria, including a silicon-28 facility in Koedoespoort producing material for advanced semiconductors and quantum computing, as well as facilities elsewhere in the city focused on lighter isotopes and ytterbium-176, which has medical applications. PET Labs produces radioactive medicines used in diagnostic scans and other nuclear-medicine procedures in Pretoria, while ASP has acquired similar specialist pharmacies in Florida and South Carolina. Quantum Leap Energy, meanwhile, is developing technology to convert and enrich uranium for use as nuclear fuel, including a planned facility at the South African Nuclear Energy Corporation’s Pelindaba complex. Yet Mann calls PET Labs and Renergen “the powerhouse of the company”, responsible for most of its near- to medium-term ebitda targets.
Renergen’s investment case rests on the Virginia Gas Project in the Free State, where Tetra4 holds South Africa’s only onshore petroleum production right. The field has a proven helium reserve of about 7.2-billion cubic feet, with average concentrations above 3%, compared with less than 0.5% in many conventional gas fields. Some wells have yielded more than 10%. Mann describes the resource as “probably one of a kind in the world”, while Renergen co-founder Nick Mitchell says its shallow depth and natural reservoir pressure should reduce drilling, compression and purification requirements relative to many competing projects.
ASP plans to transfer Renergen into Noble Africa, another wholly owned subsidiary, before taking it public through a reverse merger with Nasdaq-listed ENDRA Life Sciences. ENDRA formally remains a medical device developer, but its pre-revenue liver-imaging programme has been scaled back, and it employed only four people when the deal was announced. In practice, it is serving as a listed shell. Mann says the residual business could be “divested, sold and shut down very quickly”, while ENDRA offered a clean Nasdaq vehicle with little debt and few legacy obligations. ASP sees the reverse merger as a faster and cheaper route to market than a conventional IPO.
ENDRA would be renamed Noble Africa and intends to trade on the Nasdaq under the proposed ticker NOBA. Completion of the merger and listing is targeted for the second half of 2026, subject to US Securities & Exchange Commission registration, ENDRA shareholder approval and other conditions. ASP expects to retain about 89%, existing ENDRA shareholders roughly 3% and outside placement investors about 7%. The $50m placement includes $20m from ASP and $30m from other investors. Mann believes the separate listing will appeal to investors seeking scarce pure-play helium exposure: “We expect Noble Africa to be the only Nasdaq-listed company focused on helium production.”
For all the appeal of a fresh listing, Renergen’s poor execution record remains difficult to ignore. Phase 1 helium milestones were repeatedly deferred, while technical problems, insufficient gas flow and difficulty cooling large ISO containers prevented sustained commercial output. Renergen produced helium intermittently, but then halted further filling while developing an improved solution. Recurring material helium sales have yet to emerge.
ASP argues that the latest drilling campaign has reduced the remaining risk. Since operations restarted in April 2025, the wells have achieved the cumulative flow needed to run the phase 1 plant at nameplate capacity once pipeline tie-ins are completed. Mann says the recent success was “primarily due to the post-restart engagement of a US-based specialist” in exploration, well design, drilling and reservoir modelling. Some new wells have delivered flows more than 10 times those of earlier wells. The plant, meanwhile, “continues to supply LNG to our existing customer base” as the helium system is brought into operation.
ASP expects helium production to commence before the end of September, with phase 1 ramping to nameplate capacity during the third quarter. “We expect to begin recognising these revenues during the second half of 2026,” Mann says. The plant is designed to produce about 70,000ft³ (70Mcf) of helium and 2,500 gigajoules (GJ) of liquefied natural gas (LNG) a day. A five-year take-or-pay agreement with an Asian industrial gas company, priced above $600/Mcf, covers about 15% of helium capacity, while management hopes to contract 50%-75% of output under agreements lasting five to 15 years.
Noble Africa will initially be led by Mann and Mitchell. Former Renergen CEO Stefano Marani has moved into ASP Isotopes as president of its electronics and space division, where he oversees activities including the production scale-up and commercialisation of “enriched silicon-28 for quantum computing and next-generation semiconductors”. Mann will serve as CEO of both Renergen and the future Noble Africa, with Mitchell heading operations.
Most of Renergen’s economics sit in phase 2. Planned helium production of about 900Mcf a day would be nearly 13 times phase 1 capacity and, according to management, equivalent to 5%-7% of global supply, alongside roughly 34,000GJ of LNG. At management’s assumed prices, phase 1 could generate about $27m of annual revenue and $10m-$11m of cash gross profit, whereas phase 2 could produce more than $360m of revenue and about $300m of cash gross profit.
Phase 2 would use only 14% of the project’s acreage, leaving what Mann calls “plenty of spare resource capacity” for possible phase 3 and phase 4 developments. Renergen is also undertaking the first comprehensive update of Tetra4’s geological resource estimate since an independent assessment in 2021. The review will incorporate new aeromagnetic, gravity and seismic surveys, recent drilling and an additional reservoir body identified in the Karoo sandstone. Completion is expected in the fourth quarter of 2026.
The expected financial returns of phase 2 remain distant. The latest shareholder letter says phase 2 construction could start in the second half of 2026, but the project still requires an estimated 44-month build, with commissioning envisaged in 2030 and 2031 marking the first full year of commercial revenue. That is far removed from the original timelines promoted under the former listed Renergen and would require about $1.1bn of capital expenditure.
Financing is equally unresolved. The US International Development Finance Corporation, a phase 1 lender, has conditionally approved up to $500m of senior debt, while Standard Bank has conditionally approved another $250m. Conditions include sufficient land rights, acceptable construction arrangements, binding offtake covering at least half of debt service obligations and enough equity to keep debt to equity below 65:35. Against a $1.1bn project cost, the debt would leave a $350m funding gap; satisfying the leverage limit could require closer to $400m of equity. Noble Africa’s proposed $50m capital raise is useful development funding, not a complete phase 2 solution.
The market backdrop could hardly be better if Renergen delivers. Mann claimed that “50% of the world’s helium supply is currently offline”, citing disruption at Qatar’s Ras Laffan complex, Russian constraints and the exhaustion of the US strategic reserve. Longer term, absent substantial new capacity, supply is likely to remain concentrated and vulnerable to disruption.
That tight supply outlook is being reinforced by rising demand. Management expects consumption to grow by 5%-6% a year as semiconductor manufacturers use more helium for cooling and process control, MRI scanners rely on it to cool superconducting magnets, fibreoptic production expands and space companies consume it to pressurise and purge rocket systems.
Exports are technically demanding because liquid helium must remain near -269°C and gradually boils away. Mitchell, nevertheless, says standard 40ft ISO containers can move by road or rail to Cape Town, Gqeberha or Durban and then directly onto ships without specialist port infrastructure. Transit time matters, particularly to Asia, but contracts are expected to price product at the plant gate, shifting much of the logistics burden to customers.
Investor scepticism around Renergen is understandable. One participant on the conference call captured the South African experience: “I’ve been seeing this presentation for the best part of a decade, and the only thing that changes is the timelines. What makes this time different, and when will customers take delivery of helium?” Management’s answer was that ASP has injected capital Renergen previously lacked and brought in specialist US drilling expertise that has improved well selection and performance.
Perhaps. But before taking another leap of faith, badly burnt South African investors are likely to demand what Renergen has rarely delivered: sustained production, repeat helium deliveries and milestones achieved when promised.
